Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Non Operating Income: 2012-2022

Historic Other Non Operating Income for Enanta Pharmaceuticals (ENTA) over the last 9 years, with Jun 2022 value amounting to $393,000.

  • Enanta Pharmaceuticals' Other Non Operating Income fell 10.48% to $393,000 in Q2 2022 from the same period last year, while for Jun 2022 it was -$782,000, marking a year-over-year increase of 78.64%. This contributed to the annual value of -$27,000 for FY2021, which is 118.12% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Other Non Operating Income stood at $393,000 for Q2 2022, which was up 54.12% from $255,000 recorded in Q1 2022.
  • Enanta Pharmaceuticals' 5-year Other Non Operating Income high stood at $2.4 million for Q2 2019, and its period low was -$5.3 million during Q3 2020.
  • Over the past 3 years, Enanta Pharmaceuticals' median Other Non Operating Income value was $416,000 (recorded in 2021), while the average stood at -$104,800.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Other Non Operating Income crashed by 115.15% in 2018, and later soared by 24,050.00% in 2019.
  • Over the past 5 years, Enanta Pharmaceuticals' Other Non Operating Income (Quarterly) stood at -$100,000 in 2018, then surged by 24,050.00% to $2.1 million in 2019, then crashed by 67.39% to $677,000 in 2020, then crashed by 61.89% to $258,000 in 2021, then fell by 10.48% to $393,000 in 2022.
  • Its Other Non Operating Income stands at $393,000 for Q2 2022, versus $255,000 for Q1 2022 and $258,000 for Q4 2021.